肝移植患者中他克莫司 4 小时监测不劣于谷值监测:随机对照 FK04 试验。

Tacrolimus 4-hour monitoring in liver transplant patients is non-inferior to trough monitoring: The randomized controlled FK04 trial.

机构信息

Department of Gastroenterology and Hepatology and Transplantation Center, Leiden University Medical Center, Leiden, The Netherlands.

Department of Clinical Pharmacology and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Clin Transplant. 2022 Dec;36(12):e14829. doi: 10.1111/ctr.14829. Epub 2022 Nov 8.

Abstract

BACKGROUND

After liver transplantation (LT), tacrolimus and ciclosporin treatment can lead to, partially concentration-dependent, chronic kidney disease. Monitoring ciclosporin with two-hour levels reduced overexposure and led to better renal function than trough-monitoring (C0). For tacrolimus, a 4-hour level (C4) can give a reasonable approximation of total drug exposure. We evaluated whether monitoring tacrolimus in stable patients after LT by C4 was superior to C0 regarding renal function, rejection and metabolic parameters.

METHODS

This open label randomized controlled trial compared C4 monitoring of tacrolimus BID (Prograft) to trough (C0) monitoring in stable LT recipients. The target range for C4 of 7.8-16 ng/ml was calculated to be comparable with target C0 of 4-8 ng/ml. Primary endpoint was the effect on renal function and secondary endpoints were the occurrence of treated biopsy-proven acute rejection, blood pressure and metabolic parameters, during 3 months of follow-up.

RESULTS

Fifty patients were randomized to C0 (n = 25) or C4 (n = 25) monitoring. There was no difference in renal function between the C0 and the C4 group (p = .98 and p = .13 for CG and MDRD at 3 months). Also, the amount of proteinuria was similar (p = .59). None of the patients suffered from graft loss or was treated for rejection. Metabolic parameters did not differ between the two groups.

CONCLUSION

Tacrolimus 4-hour monitoring in stable LT patients is not superior to trough monitoring, regarding the effect on renal function, but is safe for use to facilitate tacrolimus monitoring in an afternoon outpatient clinic.

摘要

背景

肝移植(LT)后,他克莫司和环孢素治疗会导致部分浓度依赖性的慢性肾脏病。与谷值监测(C0)相比,两小时浓度监测(C2)可减少药物过量,改善肾功能。对于他克莫司,4 小时浓度(C4)可以合理地反映总药物暴露量。我们评估了 LT 后稳定患者中通过 C4 监测他克莫司是否在肾功能、排斥反应和代谢参数方面优于 C0。

方法

这项开放标签随机对照试验比较了 C4 监测他克莫司(普乐可复)bid 与 LT 稳定受者的谷值(C0)监测。C4 的目标范围为 7.8-16 ng/ml,计算结果与目标 C0 的 4-8 ng/ml 相当。主要终点是 3 个月随访期间对肾功能的影响,次要终点是治疗性活检证实的急性排斥反应、血压和代谢参数的发生。

结果

50 例患者被随机分为 C0 组(n = 25)或 C4 组(n = 25)。C0 和 C4 组之间肾功能无差异(CG 和 MDRD 在 3 个月时,p = 0.98 和 p = 0.13)。同样,蛋白尿量也相似(p = 0.59)。无患者发生移植物丢失或接受排斥反应治疗。两组之间代谢参数无差异。

结论

在 LT 稳定患者中,C4 监测他克莫司在肾功能方面并不优于谷值监测,但为在下午门诊方便进行他克莫司监测而安全使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb5/10078353/23d9c6024e08/CTR-36-0-g001.jpg

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索